ALZN — Alzamend Neuro Balance Sheet
0.000.00%
Last trade - 00:00- $4.94m
- $4.74m
Annual balance sheet for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.043 | 0.09 | 1.93 | 14.1 | 5.14 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.285 | 0.194 | 0.016 | 0 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1.5 | 1.81 | 2.91 | 14.4 | 5.84 |
| Net Property, Plant And Equipment | — | — | — | 0.103 | 0.08 |
| Total Assets | 1.5 | 1.81 | 2.91 | 14.5 | 5.92 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.18 | 0.992 | 0.9 | 1.16 | 2.87 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.18 | 0.992 | 0.9 | 1.16 | 2.87 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.317 | 0.822 | 2.01 | 13.4 | 3.05 |
| Total Liabilities & Shareholders' Equity | 1.5 | 1.81 | 2.91 | 14.5 | 5.92 |
| Total Common Shares Outstanding |